Qulab is a company that develops a platform for de-novo molecule drug design. It was established in 2017 by Alireza Shabani. Qulab is headquartered in Los Angeles, California, United States. It has received funding from investors such as Cota Capital and Plug and Play.
Qulab's main product is its software, Quleap launched in 2019. Quleap is a platform for small molecule drug design through the application of artificial intelligence and quantum computing. The software is intended to decrease the amount of time needed during the drug discovery and pre-clinical development phases. Quleap's current capabilities include de-novo molecular design as well as molecular dynamics simulation and synthesis planning. Despite its quantum computing basis, Quleap can be used in classical computers and is accessible for use in enterprise and academic settings.